Deerfield gives up rights to Windtree therapy; Travere inks deal with Renalys in Asia; Celularity raises $21M

Plus, news about Prime Med­i­cine, Sagimet Bio­sciences and Adicet Bio:

Deer­field ter­mi­nates rights to 2017 deal with Windtree Ther­a­peu­tics: The biotech last year in-li­censed Aero­surf, the acute pul­monary drug/de­vice com­bi­na­tion at the cen­ter of the Deer­field deal. Back in Au­gust, Windtree said Lee’s Phar­ma­ceu­ti­cal will de­vel­op and com­mer­cial­ize a pair of Windtree’s acute pul­monary treat­ments, in­clud­ing Aero­surf. Deer­field no longer has rights to Aero­surf’s mile­stone pay­ments, and Windtree is hand­ing over about 600,000 shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.